459 related articles for article (PubMed ID: 12814972)
21. Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes.
Yamazaki H; Urano T; Hiroki S; Shimada T
J Toxicol Sci; 1996 Nov; 21(4):215-26. PubMed ID: 8959645
[TBL] [Abstract][Full Text] [Related]
22. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
Jiang R; Yamaori S; Takeda S; Yamamoto I; Watanabe K
Life Sci; 2011 Aug; 89(5-6):165-70. PubMed ID: 21704641
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes.
Carr B; Norcross R; Fang Y; Lu P; Rodrigues AD; Shou M; Rushmore T; Booth-Genthe C
Drug Metab Dispos; 2006 Oct; 34(10):1703-12. PubMed ID: 16815964
[TBL] [Abstract][Full Text] [Related]
24. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.
Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
Drug Metab Dispos; 2010 Jun; 38(6):981-7. PubMed ID: 20203109
[TBL] [Abstract][Full Text] [Related]
25. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Hall SD; Jones DR; VandenBranden M; Wrighton SA
Biochem Pharmacol; 1994 Apr; 47(9):1643-53. PubMed ID: 8185679
[TBL] [Abstract][Full Text] [Related]
26. Effect of age on in vitro triazolam biotransformation in male human liver microsomes.
Patki KC; von Moltke LL; Harmatz JS; Hesse LM; Court MH; Greenblatt DJ
J Pharmacol Exp Ther; 2004 Mar; 308(3):874-9. PubMed ID: 14634046
[TBL] [Abstract][Full Text] [Related]
27. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.
Shen L; Fitzloff JF; Cook CS
Drug Metab Dispos; 2004 Feb; 32(2):186-96. PubMed ID: 14744940
[TBL] [Abstract][Full Text] [Related]
28. Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5.
Li X; Song X; Kamenecka TM; Cameron MD
Drug Metab Dispos; 2012 Sep; 40(9):1803-9. PubMed ID: 22696420
[TBL] [Abstract][Full Text] [Related]
29. Factors influencing midazolam hydroxylation activity in human liver microsomes.
He P; Court MH; Greenblatt DJ; von Moltke LL
Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
[TBL] [Abstract][Full Text] [Related]
30. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
[TBL] [Abstract][Full Text] [Related]
31. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
[TBL] [Abstract][Full Text] [Related]
32. In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance.
Skauby RH; Bergan S; Andersen AM; Vethe NT; Christensen H
Basic Clin Pharmacol Toxicol; 2021 Dec; 129(6):427-436. PubMed ID: 34396687
[TBL] [Abstract][Full Text] [Related]
33. The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil.
Ku HY; Ahn HJ; Seo KA; Kim H; Oh M; Bae SK; Shin JG; Shon JH; Liu KH
Drug Metab Dispos; 2008 Jun; 36(6):986-90. PubMed ID: 18308836
[TBL] [Abstract][Full Text] [Related]
34. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
Wang YH; Jones DR; Hall SD
Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
[TBL] [Abstract][Full Text] [Related]
35. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.
Galetin A; Clarke SE; Houston JB
Drug Metab Dispos; 2003 Sep; 31(9):1108-16. PubMed ID: 12920166
[TBL] [Abstract][Full Text] [Related]
36. Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes.
Lukkari E; Taavitsainen P; Juhakoski A; Pelkonen O
Pharmacol Toxicol; 1998 Apr; 82(4):161-6. PubMed ID: 9584328
[TBL] [Abstract][Full Text] [Related]
37. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
Casabar RC; Wallace AD; Hodgson E; Rose RL
Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053
[TBL] [Abstract][Full Text] [Related]
38. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
Ghosal A; Lu X; Penner N; Gao L; Ramanathan R; Chowdhury SK; Kishnani NS; Alton KB
Drug Metab Dispos; 2011 Jan; 39(1):30-8. PubMed ID: 20926621
[TBL] [Abstract][Full Text] [Related]
39. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
40. Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4.
Kanamitsu S; Ito K; Green CE; Tyson CA; Shimada N; Sugiyama Y
Pharm Res; 2000 Apr; 17(4):419-26. PubMed ID: 10870985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
